# Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.

> **NCT03164876** · PHASE1 · COMPLETED · sponsor: **Autifony Therapeutics Limited** · enrollment: 24 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AUT00206
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03164876
- **Lead sponsor:** Autifony Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-20
- **Primary completion:** 2019-04-03
- **Final completion:** 2019-04-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164876, "Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03164876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*